GZERO Media logo
{{ subpage.title }}

Why the developing world is getting left behind on vaccine rollout

For the world's wealthiest nations, including the United States, the rollout of COVID-19 vaccine has been rocky, to say the least. And as a result, much of the developing world will have to wait even longer for their turn. Part of the challenge, World Bank President David Malpass says, is that "advanced economies have reserved a lot of the vaccine doses." Malpass sat down with Ian Bremmer recently to talk about what his organization is doing to try to keep millions around the world from slipping deeper into poverty during the pandemic. Their conversation was part of the latest episode of GZERO World.

Do the global poor have a champion in the World Bank?

For the first time in twenty years, extreme poverty around the world is growing. How does the developing world recover from a pandemic that has brought even the richest nations to their knees? David Malpass, the President of the World Bank, is tasked with answering that question. He joins Ian Bremmer on GZERO World to talk about how his organization is trying to keep the developing world from slipping further into poverty in the wake of a once-in-a-century pandemic.

When will the developing world get the vaccine?

As the world's richest nations struggle with vaccine rollout, a more daunting question looms: When will the world's poorest nations get the COVID-19 vaccine? Of course, some vaccines have already reached the developing world, but World Bank President David Malpass says it may not be until the second half of 2021, or even well into 2022, that distribution becomes widespread. His conversation with Ian Bremmer is part of an upcoming episode of GZERO World, airing on public television nationwide beginning this Friday, January 15th. Check local listings.

What We’re Watching: Iran’s uranium enrichment gambit, Indian vaccine woes

Iran ups uranium enrichment: In its most flagrant violation to date of the 2015 nuclear deal, Iran confirmed that it had started enriching uranium to 20 percent purity at its Fordo facility. Under the deal, which the Trump administration abandoned in 2018, Tehran was only allowed to enrich uranium up to 3.67 percent purity (not enough to build a nuclear weapon) and was required to stop enrichment at its underground facility at Fordo altogether. Washington — and the Israelis — say this recent development reflects Iran's mendaciousness, but Tehran argues it's merely a response to the US going back on its word and imposing crippling economic sanctions in recent years that have squeezed the Iranian economy. Meanwhile, the Iranians have also engaged in bellicose activities in the volatile Strait of Hormuz, seizing a South Korean tanker that it says breached its maritime sovereignty. This week also marks one year since the US slaying of Iranian general Qassim Suleimani, an event that ratcheted up US-Iranian tensions — and one that Tehran has vowed to avenge in due time.

Read Now Show less

What We’re Watching: EU vaccination campaign, Indian farm bill talks, two elections in Africa

EU rolls out vaccines: As COVID-19 cases and deaths continue to rise throughout the European Union, the bloc on Sunday officially kicked off its campaign to vaccinate roughly 450 million EU residents against the disease. But even as shoulders are bared for the needle across the Union, two fights are already brewing about the process. First, Italy is concerned that Germany may be getting more than its fair share of the precious shots based on its population — as agreed to by EU member states — because a German company, BioNTech, jointly developed the EU-approved vaccine with US pharmaceutical giant Pfizer. Second, problems with maintaining the drugs at the required ultra-cold temperature have already led to vaccination delays in Spain. The challenges now are to ensure all EU member states inoculate their residents at a similar pace, to overcome vaccine skepticism across the bloc, and to avoid shortages while waiting for other vaccine candidates to get approved.

Read Now Show less

Latest